SAGE Therapeutics (SAGE) Received its Third Buy in a Row


After Morgan Stanley and Piper Jaffray gave SAGE Therapeutics (NASDAQ: SAGE) a Buy rating last month, the company received another Buy, this time from RBC Capital. Analyst Brian Abrahams reiterated a Buy rating on SAGE Therapeutics yesterday and set a price target of $255. The company’s shares closed yesterday at $151.20.

According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 12.3% and a 55.1% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, Alder Biopharmaceuticals, and Intra-Cellular Therapies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for SAGE Therapeutics with a $217.43 average price target, representing a 43.8% upside. In a report issued on August 6, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $206 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $195.97 and a one-year low of $59.57. Currently, SAGE Therapeutics has an average volume of 532K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts